BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 30854074)

  • 1. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.
    Xu Y; Cui G; Jiang Z; Li N; Zhang X
    Oncol Lett; 2019 Mar; 17(3):2960-2968. PubMed ID: 30854074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma.
    Assal RA; Elemam NM; Mekky RY; Attia AA; Soliman AH; Gomaa AI; Efthimiadou EK; Braoudaki M; Fahmy SA; Youness RA
    Transl Oncol; 2024 Jul; 45():101961. PubMed ID: 38631259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
    Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of PD-L1 protein expression and CD8
    Sun Y; Zhai C; Chen X; Dong Z; Hou L; Zhou C; Jiang T
    Transl Lung Cancer Res; 2019 Dec; 8(6):748-759. PubMed ID: 32010554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD155 immunohistochemical expression in upper tract urothelial carcinoma predicts poor prognosis.
    Ikeda J; Ohe C; Yoshida T; Saito R; Tsuta K; Kinoshita H
    Oncol Lett; 2022 Nov; 24(5):414. PubMed ID: 36245820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Predicts Poor Prognosis in Surgically Resected Limited Stage Small-Cell Lung Cancer.
    Fu X; Liu Z; Xiang L; Liu M; Zheng X; Wang J; Liu N; Gao H; Jiang A; Yang Y; Liang X; Ruan Z; Tian T; Yao Y
    Cancer Manag Res; 2020; 12():10939-10948. PubMed ID: 33154673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
    Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W
    Front Immunol; 2022; 13():1058424. PubMed ID: 36544779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer.
    Albrecht T; Brinkmann F; Albrecht M; Lonsdorf AS; Mehrabi A; Hoffmann K; Kulu Y; Charbel A; Vogel MN; Rupp C; Köhler B; Springfeld C; Schirmacher P; Roessler S; Goeppert B
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33918309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
    Ishihara S; Iwasaki T; Kohashi K; Kawaguchi K; Toda Y; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2425-2436. PubMed ID: 35737088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
    Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
    Siebert N; Zumpe M; Schwencke CH; Biskupski S; Troschke-Meurer S; Leopold J; Zikoridse A; Lode HN
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
    Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
    Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
    J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
    Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
    Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment.
    Wang RB; Li YC; Zhou Q; Lv SZ; Yuan KY; Wu JP; Zhao YJ; Song QK; Zhu B
    World J Clin Cases; 2020 Dec; 8(23):5935-5943. PubMed ID: 33344592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
    Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
    Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD39: the potential target in small cell lung cancer.
    Chen S; Wu S; Zhang L; Zhang W; Liu Y; Chen B; Zhao S; Li W; Sun C; Wang L; Jia K; Wang H; Chen P; Wu C; Zhu J; He Y; Zhou C
    Transl Lung Cancer Res; 2020 Aug; 9(4):1483-1495. PubMed ID: 32953520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus.
    Zhao K; Ma L; Feng L; Huang Z; Meng X; Yu J
    Front Mol Biosci; 2020; 7():608404. PubMed ID: 33490104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
    Shen M; Jiang K; Sui Y; Xu Z; Cui H; Wang Y; Zhang H; Xu Z; Xu W; Ding Q; Chen Y
    Lung Cancer; 2021 Oct; 160():84-91. PubMed ID: 34479175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
    Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
    J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.